Can AI Machine Learning Be Used to Improve Cancer Screening?

4min Snip

00:00

Play full episode

Summary

Transcript

Episode notes

On the big data, an AI machine learning piece, curious to understand how are you at garden kind of mobilizing the vast datasets now that you've read hundreds of thousands of tests. Our tagline of the company is concur cancer data. We kept the tagline the same because we continue to believe in it and we are seeing in the way we are building the next set of products, technology stacks, our offerings. Yeah, that's definitely a lot of exciting innovations across the landscape.

This week, we’re super excited to have AmirAli Talasaz, co-CEO and co-founder of Guardant Health, a leading precision oncology company focused on helping conquer cancer globally.

Founded in 2011, Guardant Health is focused on helping conquer cancer through the use of its proprietary blood-based tests, vast data sets and advanced analytics. Guardant’s solutions include treatment selection, recurrence detection and early detection of cancer. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum.

Through multiple rounds of private financing, Guardant Health raised over $500 million from investors including Sequoia, Khosla, Lightspeed, OrbiMed, and Softbank, and Pear! and Guardant completed a successful IPO in October 2018.